BeiGene Ltd.
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
- Conditions
- Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 510
- Registration Number
- NCT04002297
- Locations
- 🇦🇺
Calvary Mater Newcastle, Waratah, New South Wales, Australia
🇦🇺Icon Cancer Foundation, South Brisbane, Queensland, Australia
🇦🇺Royal Hobart Hospital, Hobart, Tasmania, Australia
Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 25
- Registration Number
- NCT03994211
- Locations
- 🇬🇪
Arensia Exploratory Medicine Llc, Tbilisi, Georgia
🇵🇱Szpital Luxmed, Warszawa, Poland
🇸🇰Summit Clinical Research, Sro, Bratislava, Slovakia
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 4
- Registration Number
- NCT03991494
- Locations
- 🇬🇧
The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom
🇬🇧Royal Liverpool University Hospital Clinical Research Unit, Liverpool, United Kingdom
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2019-05-30
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 420
- Registration Number
- NCT03967977
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
- Interventions
- First Posted Date
- 2019-05-21
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 370
- Registration Number
- NCT03957590
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳The First Affiliated Hospitalschool of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China
🇨🇳Jieyang Peoples Hospital (Jieyang Affiliated Hospital, Sun Yat Sen University ), Jieyang, Guangdong, China
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
- Conditions
- Carcinoma, HepatocellularGastric/Gastroesophageal Junction Cancer
- Interventions
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 111
- Registration Number
- NCT03941873
- Locations
- 🇨🇳
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North), Guangzhou, Guangdong, China
🇨🇳Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
- Conditions
- Recurrent or Metastatic Nasopharyngeal Cancer
- Interventions
- First Posted Date
- 2019-04-23
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 263
- Registration Number
- NCT03924986
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
- Conditions
- Solid Tumor, Adult
- Interventions
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 93
- Registration Number
- NCT03905148
- Locations
- 🇺🇸
University of California Los Angeles, Santa Monica, California, United States
🇺🇸MD Anderson, Houston, Texas, United States
🇦🇺Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 68
- Registration Number
- NCT03846427
- Locations
- 🇺🇸
Clinical Research Alliance, Inc, Westbury, New York, United States
🇺🇸The Charlotte Mecklenburg Hospital Authority, Charlotte, North Carolina, United States
🇦🇺The Saint George Hospital Kogarah, Kogarah, New South Wales, Australia
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 649
- Registration Number
- NCT03783442
- Locations
- 🇺🇸
Smilow Cancer Hospital at Yale-New Haven - Neurology, New Haven, Connecticut, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Allegheny General Hospital (AGH), Pittsburgh, Pennsylvania, United States